ONCT (Oncternal Corp) Company Cash on Hand

Oncternal Therapeutics (ONCT) faces a critical cash shortage and the threat of delisting. This chart in the GURU.Markets terminal illustrates the cash balance, where 0.01 shows the value of this parameter. The company generates revenue through partnerships, developing treatments for leukemia and prostate cancer while adhering to strict bioethical standards and minimizing harmful emissions in its laboratories.
Financial and market metric breakdowns for Oncternal Therapeutics, Inc. (ONCT)

Liquidity assessment is critical for capital protection amid uncertainty. This metric measures the volume of available cash to settle short-term obligations without compromising operational activities. By analyzing cash-on-hand, an investor can filter out companies at risk of cash flow gaps. For Oncternal Therapeutics (ONCT), this reserve secures the funding for the development of targeted drugs. The availability of liquidity supports the value of patents until the company reaches break-even.